Abstract: Disclosed are target for screening anti-tumor drug, application use thereof and screening method therefor. Disclosed are a target for screening a drug for treating and/or preventing tumors, the target for screening the drug for treating and/or preventing tumors comprise selenoprotein; and a target for screening a drug for preventing tumor metastasis, the target for screening the drug for preventing the tumor metastasis comprising selenoprotein. Also disclosed is a method for screening a drug for treating and/or preventing tumors or a drug for preventing tumor metastasis, the method comprising: interacting a candidate drug with the selenoprotein; and screening the drug for treating and/or preventing tumors or the drug for preventing tumor metastasis according to an affinity between the candidate drug and the selenoprotein; and the candidate drug with a high affinity with the selenoprotein is taken as a candidate primarily screened drug.

Abstract: The present disclosure provides a spiramycin-producing strain, a carrimycin-producing strain, construction method therefor, use thereof and method for increasing the product yield thereof. The provided spiramycin-producing strain has an inactivated gene Lrp (?lrp-SP); and the strain has a preservation number of CGMCC No.16056. The provided carrimycin-producing strain has an inactivated gene Lrp (?lrp-BT); and the strain has a preservation number of CGMCC No.16055. By inactivating the gene Lrp, the yields of spiramycin and carrimycin are increased; and particularly the yield and proportion of a major component of the carrimycin, that is, 4?-O-isovalerylspiramycin III are significantly increased.

Abstract: A medicament for preventing, alleviating and/or treating fibrosis comprises one of Carrimycin, Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III; or a combination of two or three of Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III. A combination product for preventing, alleviating and/or treating fibrosis comprises a first drug, an effective component of the first drug comprises one of Carrimycin, Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III; or a combination of two or three of Isovalerylspiramycin I, Isovalerylspiramycin II and Isovalerylspiramycin III. It also relates to use of the medicine and combination product in preventing, alleviating and/or treating fibrosis.

Abstract: Use of carrimycin in Mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in Mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated Mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle Bacillus infected diseases are expected to be developed.

Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).

Abstract: A method, a system and a terminal for identity authentication, and a computer readable storage medium are provided. The method includes: acquiring a human body image of a person to be authenticated, and determining from the human body image a plurality of skeleton key points of the person to be authenticated; converting the skeleton key points into feature data, and combining the feature data to form physique feature information characterizing the person to be authenticated; processing the physique feature information using a physique feature model by inputting the physique feature information into the physique feature model, to obtain a processing result; and recognizing the identity of the person to be authenticated based on the processing result of the physique feature model.

Abstract: A method, a system and a terminal for identity authentication, and a computer readable storage medium are provided. The method for identity authentication includes: acquiring a facial image of a person to be authenticated, and determining from the facial image facial feature information of the person to be authenticated; determining a suspected object using a face authentication platform according to the facial feature information of the person to be authenticated; acquiring a human body image of the person to be authenticated, and determining from the human body image a plurality of skeleton key points of the person to be authenticated; converting the skeleton key points into feature data; and recognizing an identity of the person to be authenticated according to the feature data of the person to be authenticated and information of the suspected object.

Abstract: Disclosed are a medicament comprising isovaleryl spiramycin I, II and/or III, and use of isovaleryl spiramycin I, II and/or III in manufacturing medicament for treating and/or preventing tumor and the medicament.

Abstract: A method, a system and a terminal for identity authentication, and a computer readable storage medium are provided. The method includes: acquiring a human body image of a person to be authenticated, and determining from the human body image a plurality of skeleton key points of the person to be authenticated; converting the skeleton key points into feature data, and combining the feature data to form physique feature information characterizing the person to be authenticated; processing the physique feature information using a physique feature model by inputting the physique feature information into the physique feature model, to obtain a processing result; and recognizing the identity of the person to be authenticated based on the processing result of the physique feature model.

Abstract: A method, a system and a terminal for identity authentication, and a computer readable storage medium are provided. The method for identity authentication includes: acquiring a facial image of a person to be authenticated, and determining from the facial image facial feature information of the person to be authenticated; determining a suspected object using a face authentication platform according to the facial feature information of the person to be authenticated; acquiring a human body image of the person to be authenticated, and determining from the human body image a plurality of skeleton key points of the person to be authenticated; converting the skeleton key points into feature data; and recognizing an identity of the person to be authenticated according to the feature data of the person to be authenticated and information of the suspected object.

Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).

Abstract: Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.